vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and First Foundation Inc. (FFWM). Click either name above to swap in a different company.
4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $48.4M, roughly 1.8× First Foundation Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs -97.9%, a 120.7% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 421.7%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $-35.2M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs -2.7%).
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
John B. Lacson Colleges Foundation (Bacolod), Inc. is a private maritime college in Bacolod, Negros Occidental, Philippines.
FDMT vs FFWM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $48.4M |
| Net Profit | $19.4M | $-8.0M |
| Gross Margin | — | — |
| Operating Margin | 17.3% | -97.5% |
| Net Margin | 22.8% | -97.9% |
| Revenue YoY | 8508900.0% | 421.7% |
| Net Profit YoY | 139.1% | 43.0% |
| EPS (diluted) | $0.43 | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $85.1M | $48.4M | ||
| Q3 25 | $90.0K | $63.6M | ||
| Q2 25 | $15.0K | $51.4M | ||
| Q1 25 | $14.0K | $71.4M | ||
| Q4 24 | $1.0K | $9.3M | ||
| Q3 24 | $3.0K | $9.2M | ||
| Q2 24 | $5.0K | $57.5M | ||
| Q1 24 | $28.0K | $51.1M |
| Q4 25 | $19.4M | $-8.0M | ||
| Q3 25 | $-56.9M | $-146.3M | ||
| Q2 25 | $-54.7M | $-7.7M | ||
| Q1 25 | $-48.0M | $6.9M | ||
| Q4 24 | — | $-14.1M | ||
| Q3 24 | $-43.8M | $-82.2M | ||
| Q2 24 | $-35.0M | $3.1M | ||
| Q1 24 | $-32.4M | $793.0K |
| Q4 25 | 17.3% | -97.5% | ||
| Q3 25 | -67983.3% | -92.7% | ||
| Q2 25 | -396373.3% | -21.1% | ||
| Q1 25 | -383007.1% | 8.8% | ||
| Q4 24 | — | -247.7% | ||
| Q3 24 | -1704400.0% | -1276.7% | ||
| Q2 24 | -849120.0% | 4.6% | ||
| Q1 24 | -136200.0% | -0.2% |
| Q4 25 | 22.8% | -97.9% | ||
| Q3 25 | -63195.6% | -230.1% | ||
| Q2 25 | -364386.7% | -15.0% | ||
| Q1 25 | -342657.1% | 9.7% | ||
| Q4 24 | — | -152.2% | ||
| Q3 24 | -1461433.3% | -896.9% | ||
| Q2 24 | -699060.0% | 5.4% | ||
| Q1 24 | -115717.9% | 1.6% |
| Q4 25 | $0.43 | $-0.09 | ||
| Q3 25 | $-1.01 | $-1.78 | ||
| Q2 25 | $-0.98 | $-0.09 | ||
| Q1 25 | $-0.86 | $0.08 | ||
| Q4 24 | — | $-0.24 | ||
| Q3 24 | $-0.79 | $-1.23 | ||
| Q2 24 | $-0.63 | $0.05 | ||
| Q1 24 | $-0.66 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | $1.6B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $505.7M | $912.6M |
| Total Assets | $566.7M | $11.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $402.7M | $1.6B | ||
| Q3 25 | $305.1M | $1.7B | ||
| Q2 25 | $293.2M | $1.1B | ||
| Q1 25 | $321.4M | $1.0B | ||
| Q4 24 | $424.9M | $1.0B | ||
| Q3 24 | $501.9M | $1.1B | ||
| Q2 24 | $541.9M | $1.4B | ||
| Q1 24 | $525.9M | $1.6B |
| Q4 25 | $505.7M | $912.6M | ||
| Q3 25 | $369.0M | $917.9M | ||
| Q2 25 | $420.9M | $1.1B | ||
| Q1 25 | $469.7M | $1.1B | ||
| Q4 24 | $510.6M | $1.1B | ||
| Q3 24 | $552.9M | $1.1B | ||
| Q2 24 | $588.3M | $933.2M | ||
| Q1 24 | $600.6M | $928.7M |
| Q4 25 | $566.7M | $11.9B | ||
| Q3 25 | $424.0M | $11.9B | ||
| Q2 25 | $473.6M | $11.6B | ||
| Q1 25 | $515.7M | $12.6B | ||
| Q4 24 | $560.4M | $12.6B | ||
| Q3 24 | $604.0M | $13.4B | ||
| Q2 24 | $620.1M | $13.7B | ||
| Q1 24 | $629.9M | $13.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | $-31.9M |
| Free Cash FlowOCF − Capex | $28.5M | $-35.2M |
| FCF MarginFCF / Revenue | 33.5% | -72.8% |
| Capex IntensityCapex / Revenue | 0.1% | 6.9% |
| Cash ConversionOCF / Net Profit | 1.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | $-45.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.6M | $-31.9M | ||
| Q3 25 | $-46.5M | $9.2M | ||
| Q2 25 | $-43.4M | $-16.3M | ||
| Q1 25 | $-47.8M | $-552.0K | ||
| Q4 24 | $-134.6M | $-8.7M | ||
| Q3 24 | $-29.4M | $14.2M | ||
| Q2 24 | $-30.2M | $-9.1M | ||
| Q1 24 | $-29.1M | $7.2M |
| Q4 25 | $28.5M | $-35.2M | ||
| Q3 25 | $-46.6M | $8.6M | ||
| Q2 25 | $-43.4M | $-16.7M | ||
| Q1 25 | $-48.4M | $-2.5M | ||
| Q4 24 | $-138.4M | $-11.4M | ||
| Q3 24 | $-31.2M | $13.4M | ||
| Q2 24 | $-30.6M | $-9.4M | ||
| Q1 24 | $-29.8M | $5.9M |
| Q4 25 | 33.5% | -72.8% | ||
| Q3 25 | -51765.6% | 13.5% | ||
| Q2 25 | -289620.0% | -32.4% | ||
| Q1 25 | -345635.7% | -3.5% | ||
| Q4 24 | -13837100.0% | -123.5% | ||
| Q3 24 | -1038966.7% | 146.2% | ||
| Q2 24 | -611840.0% | -16.3% | ||
| Q1 24 | -106421.4% | 11.6% |
| Q4 25 | 0.1% | 6.9% | ||
| Q3 25 | 101.1% | 1.0% | ||
| Q2 25 | 440.0% | 0.8% | ||
| Q1 25 | 4507.1% | 2.8% | ||
| Q4 24 | 378600.0% | 29.4% | ||
| Q3 24 | 59266.7% | 9.0% | ||
| Q2 24 | 6980.0% | 0.4% | ||
| Q1 24 | 2535.7% | 2.5% |
| Q4 25 | 1.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.96× | ||
| Q1 24 | — | 9.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
